Description

Simple

Clinical

Overview

Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.

Pharmacology

Indication

Investigated for use/treatment in anesthesia (unspecified).

Pharmacodynamic

Gantacurium chloride administered to anesthetized and ventilated healthy volunteers, caused dose dependent transient decrease in arterial blood pressure, mild histamine release at higher doses and no consistent changes in pulmonary compliance.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

3.09±0.21 minutes

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Gantacurium
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1,10-Phenanthroline
The therapeutic efficacy of Gantacurium can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Gantacurium is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Gantacurium.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Gantacurium.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Gantacurium is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Gantacurium.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Gantacurium is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Gantacurium.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Gantacurium.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Gantacurium.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Gantacurium.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Gantacurium is combined with Acetylglycinamide chloral hydrate.
Aclidinium
Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Acotiamide
The therapeutic efficacy of Gantacurium can be decreased when used in combination with Acotiamide.
Adinazolam
The risk or severity of adverse effects can be increased when Adinazolam is combined with Gantacurium.
Adipiplon
The risk or severity of adverse effects can be increased when Gantacurium is combined with Adipiplon.
Agmatine
The risk or severity of adverse effects can be increased when Gantacurium is combined with Agmatine.
Agomelatine
The risk or severity of adverse effects can be increased when Gantacurium is combined with Agomelatine.
Ajulemic acid
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Gantacurium.
Alaproclate
The risk or severity of adverse effects can be increased when Gantacurium is combined with Alaproclate.
2 References
  1. 1 . Heerdt PM, Kang R, The' A, Hashim M, Mook RJ Jr, Savarese JJ: Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. Anesthesiology. 2004 Apr;100(4):846-51.PubMed: 15087619
  2. 2 . Savarese JJ, Belmont MR, Hashim MA, Mook RA Jr, Boros EE, Samano V, Patel SS, Feldman PL, Schultz JA, McNulty M, Spitzer T, Cohn DL, Morgan P, Wastila WB: Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium. Anesthesiology. 2004 Apr;100(4):835-45.PubMed: 15087618